case report Synchronous Pneumonitis, Hepatitis and Enteritis Under Treatment with PI3kδ Inhibitor Idelalisib for Follicular Lymphoma
Maria Vergoulidou*, Diana Japaridze, Norbert Grobe
First Internal Medicine Department, Hematology and Oncology, Dietrich Bonhoeffer Klinikum Neubrandenburg, Germany
*Corresponding author: Maria Vergoulidou, First Internal Medicine Department, Hematology and Oncology, Dietrich Bonhoeffer Klinikum Neubrandenburg, Germany. Email: marivergi@yahoo.com
Received Date: 30 May, 2018; Accepted
Date: 10 June, 2018; Published Date: 19 June, 2018
Citation: Vergoulidou M, Japaridze D, Grobe N (2018) Synchronous Pneumonitis, Hepatitis and Enteritis Under Treatment with PI3kδ Inhibitor Idelalisib for Follicular Lymphoma. Hem Disease Therapies: JHDT-115. DOI: 10.29011/2577-1418. 000015
1. Abstract
Idelalisib is approved for the treatment of relapsed follicular lymphoma. We report a case with multiple toxicities during treatment including pneumonitis, hepatitis and enteritis. Toxicities resolved under supportive treatment. Idelalisib was discontinued. Our patient achieved partial remission of follicular lymphoma and had no further late complications.
2. Keywords: Enteritis; Follicular Lymphoma Case Report; Hepatitis, Idelalisib; Pneumonitis
Figure 1: Elevation of
transaminases (ALAT: serum
alanine, ASAT: aspartate aminotransferase). Normal range 0,17-0,85 μmol/l.
